BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3028922)

  • 1. Effects of a kappa-opioid agonist on adrenocorticotropic and diuretic function in man.
    Pfeiffer A; Knepel W; Braun S; Meyer HD; Lohmann H; Brantl V
    Horm Metab Res; 1986 Dec; 18(12):842-8. PubMed ID: 3028922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kappa agonist-induced diuresis: evidence for stereoselectivity, strain differences, independence of hydration variables and a result of decreased plasma vasopressin levels.
    Leander JD; Hart JC; Zerbe RL
    J Pharmacol Exp Ther; 1987 Jul; 242(1):33-9. PubMed ID: 3039112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kappa-opioid receptor agonist MR-2034 stimulates the rat hypothalamic-pituitary-adrenal axis: studies in vivo and in vitro.
    Calogero AE; Scaccianoce S; Burrello N; Nicolai R; Muscolo LA; Kling MA; Angelucci L; D'Agata R
    J Neuroendocrinol; 1996 Aug; 8(8):579-85. PubMed ID: 8866244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diuretic effect of bremazocine, a kappa-opioid with central and peripheral sites of action.
    Salas SP; Roblero J; Ureta H; Huidobro-Toro JP
    J Pharmacol Exp Ther; 1989 Sep; 250(3):992-9. PubMed ID: 2550625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diuresis and suppression of vasopressin by kappa opioids: comparison with mu and delta opioids and clonidine.
    Leander JD; Zerbe RL; Hart JC
    J Pharmacol Exp Ther; 1985 Aug; 234(2):463-9. PubMed ID: 2991502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central kappa- and mu-opiate receptors mediate ACTH-release in rats.
    Pfeiffer A; Herz A; Loriaux DL; Pfeiffer DG
    Endocrinology; 1985 Jun; 116(6):2688-90. PubMed ID: 2986960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. kappa-Opioid agonist, U50,488H, stimulates ovine fetal pituitary-adrenal function via hypothalamic arginine-vasopressin and corticotrophin-releasing factor.
    Taylor CC; Wu D; Soong Y; Yee JS; Szeto HH
    J Pharmacol Exp Ther; 1996 May; 277(2):877-84. PubMed ID: 8627570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anterior pituitary hormone responses to a kappa-opioid agonist in man.
    Pfeiffer A; Braun S; Mann K; Meyer HD; Brantl V
    J Clin Endocrinol Metab; 1986 Jan; 62(1):181-5. PubMed ID: 3079599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine actions of opioids.
    Pfeiffer A; Herz A
    Horm Metab Res; 1984 Aug; 16(8):386-97. PubMed ID: 6088380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further study of kappa opioids on increased urination.
    Leander JD
    J Pharmacol Exp Ther; 1983 Oct; 227(1):35-41. PubMed ID: 6137557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychotomimesis mediated by kappa opiate receptors.
    Pfeiffer A; Brantl V; Herz A; Emrich HM
    Science; 1986 Aug; 233(4765):774-6. PubMed ID: 3016896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo binding of benzomorphans to mu, delta and kappa opioid receptors: comparison with urine output in the rat.
    Richards ML; Sadée W
    J Pharmacol Exp Ther; 1985 May; 233(2):425-32. PubMed ID: 2987482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of CRF in the release of ACTH by opiate agonists and antagonists in rats.
    Nikolarakis K; Pfeiffer A; Stalla GK; Herz A
    Brain Res; 1987 Sep; 421(1-2):373-6. PubMed ID: 2825911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opiate receptor blockade and diurnal pituitary and adrenal hormone levels.
    Leslie RD; Prescott RW; Kendall-Taylor P; Cook D; Weightman D; Ratcliffe J; Ingram MC
    Horm Metab Res; 1985 Feb; 17(2):86-9. PubMed ID: 2985486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kappa opioid partial agonist activity of the enkephalin-like pentapeptide BW942C based on urination and in vitro studies in humans and animals.
    Vaupel DB; Cone EJ; Johnson RE; Su TP
    J Pharmacol Exp Ther; 1990 Jan; 252(1):225-34. PubMed ID: 2153801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the opioid activity of CAM and kappa agonists.
    Furst S; Friedmann T; Kovacs A; Wagner T
    NIDA Res Monogr; 1986; 75():224-7. PubMed ID: 2828975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating aspects of opioid receptor binding by [3H](-) (1R,5R,9R,2''S)-5,9-dimethyl-2-tetrahydrofurfuryl-2'-hydroxy-6,7- benzomorphan hydrochloride ([3H]Mr 2034), a drug preferentially acting on kappa-receptors.
    Ensinger HA
    Arzneimittelforschung; 1985; 35(1A):447-51. PubMed ID: 2985096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of kappa-opiate receptor antagonist MR-2266-BS on ACTH and prolactin release].
    Xu RK; Chen L; Li H; Yang SJ; Huang XY
    Sheng Li Xue Bao; 1989 Aug; 41(4):395-401. PubMed ID: 2557673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular and respiratory effects of mu-, delta- and kappa-opiate agonists microinjected into the anterior hypothalamic brain area of awake rats.
    Pfeiffer A; Feuerstein G; Kopin IJ; Faden AI
    J Pharmacol Exp Ther; 1983 Jun; 225(3):735-41. PubMed ID: 6306217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kappa opiate agonists modulate the hypothalamic-pituitary-adrenocortical axis in the rat.
    Iyengar S; Kim HS; Wood PL
    J Pharmacol Exp Ther; 1986 Aug; 238(2):429-36. PubMed ID: 3016237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.